Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) pharminent April 30, 2026
Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Policy / Pricing Regeneron cuts White House pricing deal, offers new gene therapy for free pharminent April 24, 2026
Policy / Pricing CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices pharminent April 23, 2026
Policy / Pricing Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care pharminent April 23, 2026
Policy / Pricing FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars pharminent April 22, 2026
Policy / Pricing Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients pharminent April 22, 2026
Policy / Pricing Medicare obesity drug pilot extended after insurer pushback pharminent April 22, 2026
Policy / Pricing FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development pharminent April 20, 2026
Policy / Pricing Trump backs psychedelics for mental health in new executive order pharminent April 20, 2026
Policy / Pricing RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media pharminent April 17, 2026
Policy / Pricing Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director pharminent April 16, 2026
Policy / Pricing FDA accelerated approval path needs improvement, says ICER pharminent April 16, 2026
Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results pharminent April 13, 2026
Policy / Pricing RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders pharminent April 10, 2026
Policy / Pricing The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) pharminent April 9, 2026
Policy / Pricing List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun) pharminent April 8, 2026
Policy / Pricing AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies pharminent April 7, 2026
Policy / Pricing FDA floats new clinical trial reforms; Takeda punts Denali brain drug pharminent April 6, 2026
